A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
收藏DataCite Commons2025-06-01 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002123/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC)
提供机构：
Vivli
创建时间：
2018-10-27
